Skip to main content
    O

    Opus Genetics, Inc. (IRD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.04
    +0.06 (+1.51%)

    Market Cap: $384.68M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Opus Genetics, Inc. (IRD) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Opus Genetics (IRD) trades at 52.0x sales and 10.7x book value. Its P/B of 10.7x is above its 5-year median of 2.9x. Its forward P/E is 12.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E12.0x
    Price to sales52.0x
    Price to book10.7x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 234.4% above 3.2x.

    MultipleCurrent5-year median10-year median
    P/B10.7x2.9x3.2x
    Medians of month-end values through Oct 2026: 54 months (5-year) and 114 months (10-year).

    Valuation History

    Over the 4 of the 10 year ends shown that have a P/S, its P/S ranged from 1.9x in 2022 to 9.0x in 2025. 2025 was the highest of those years.

    Year endPriceP/EP/SP/B
    2025$2.01N/A9.0x81.5x
    2024$1.19N/A3.0x5.6x
    2023$3.01N/A3.4x1.3x
    2022$3.534.1x1.9x6.1x
    2021$3.73N/AN/A3.1x
    2020$6.49N/AN/A4.3x
    2019$7.64N/AN/A0.7x
    2018$44.66N/AN/A4.6x
    2017$97.00N/AN/A3.8x
    2016$68.14N/AN/A1.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About IRD

    What is IRD's forward P/E ratio?

    Opus Genetics has a forward P/E ratio of 12.0x.

    Is IRD stock overvalued?

    GNG's valuation label for IRD is Overvalued.

    What is IRD's price to sales ratio?

    Opus Genetics has a price to sales ratio of 52.0x.